3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
154
Lymphoma
78
Lymphoma, Non-Hodgkin
62
Neoplasms, Plasma Cell
54
Leukemia
52
Leukemia, Myeloid, Acute
49
Hodgkin Disease
48
Precursor Cell Lymphoblastic Leukemia-Lymphoma
45
Leukemia, Lymphocytic, Chronic, B-Cell
45
Myelodysplastic Syndromes
42
Lymphoma, Large B-Cell, Diffuse
41
Lymphoma, Follicular
40
Lymphoma, Mantle-Cell
38
Lymphoma, Large-Cell, Immunoblastic
29
Neuroblastoma
27
Burkitt Lymphoma
27
Lymphoma, B-Cell, Marginal Zone
26
Recurrence
22
Immunoglobulin Light-chain Amyloidosis
22
Myeloproliferative Disorders
18
Leukemia, Myeloid, Accelerated Phase
16
Hematologic Neoplasms
16
Congenital Abnormalities
16
Leukemia, Myeloid, Chronic-Phase
14
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
14
Graft vs Host Disease
14
Dendritic Cell Sarcoma, Interdigitating
14
Waldenstrom Macroglobulinemia
13
Leukemia, Myelomonocytic, Chronic
13
Blast Crisis
13
Interventions
Lenalidomide
4
Bortezomib
4
Dexamethasone
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
liposomal doxorubicin
2
Doxorubicin
2
tremelimumab
1
tivozanib
1
ricolinostat
1
pomalidomide
1
pazopanib
1
nilotinib
1
durvalumab
1
avelumab
1
abexinostat
1
Transplantation, Autologous
1
Tamoxifen
1
Steroids
1
Standard of Care
1
Practice Guidelines as Topic
1
Parenteral Nutrition
1
Palliative Care
1
Paclitaxel
1
Nivolumab
1
NVP-BKM120
1
Melphalan
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Disease Progression
×
Melphalan
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts